Selective mAChR M4 Antagonists for Parkinson's Efficacy
Solution Overview
Problem
Current treatments for Parkinson's disease using muscarinic acetylcholine receptor (mAChR) antagonists are limited by dose-limiting adverse effects, which restrict the clinical utility and may underestimate the efficacy due to inability to achieve more complete blockade of specific mAChR subtypes responsible for antiparkinsonian effects.
Innovation Solution
Development of compounds with a more selective profile for individual mAChR subtypes, particularly targeting the M4 subtype, to enhance antiparkinsonian effects while minimizing adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective mAChR antagonists are used to achieve complete blockade of mAChR subtypes, then antiparkinsonian efficacy is improved, but adverse effects increase due to blockade of mAChR subtypes not involved in antiparkinsonian activity
Solution Approach 1:
The patent segments the mAChR receptor into specific subtypes (M1-M5) and develops antagonists that selectively target individual subtypes rather than providing nonselective blockade. This allows achievement of complete blockade of parkinsonian-related subtypes while avoiding blockade of subtypes responsible for adverse effects, thus resolving the contradiction between efficacy and tolerability
Solution Approach 2:
The patent applies local quality by creating subtype-specific antagonists with distinct binding characteristics for different mAChR subtypes. Each antagonist is designed to preferentially bind to specific subtypes (e.g., M1, M4) over others, enabling localized pharmacological action at the receptor subtype level to achieve therapeutic effects without widespread adverse effects
2Reliability
If dose of mAChR antagonists is increased to achieve more complete blockade, then antiparkinsonian effects are improved, but adverse effects increase due to dose-limiting side effects
Solution Approach 1:
By segmenting the receptor target into specific subtypes and developing selective antagonists, the patent enables achieving complete blockade of parkinsonian-related subtypes at lower doses, avoiding the need to increase dose to achieve therapeutic effect while thereby avoiding dose-limiting adverse effects
Solution Approach 2:
The patent changes the pharmacological parameter of receptor selectivity to achieve superior therapeutic index. By modifying the binding profile to be subtype-specific rather than nonselective, the patent achieves complete blockade of relevant subtypes at lower effective concentrations, thereby reducing adverse effects that limit dose tolerance
Data Source
AI summary
Disclosed herein are (6-(4-(trifluoromethyl)pyridin-3-yl)pyridazin-3-yl)octahydrocyclopenta[c]pyrrol-5-amine, (6-(4-(difluoromethyl)pyridin-3-yl)pyridazin-3-yl)octahydrocyclopenta[c]pyrrol-5-amine, and (6-(2-(trifluoromethyl)pyridin-3-yl)pyridazin-3-yl)octahydrocyclopenta[c]pyrrol-5-amine compounds, useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.